stockrow
Saturday 7 November 2026
Export AVIR’s income statement to Excel — free account
Atea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
- EPS
- +6.82%
- Free cash flow
- +85.5%
Quarter to June 2026, against a year earlier
4.29
0.07
+1.66%
Follow AVIR
Alert me
Atea Pharmaceuticals, Inc. (AVIR) P/E ratio
Atea Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 236× (March 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 6.1× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2021 | 6.1× | (53.35%) |
| Sep 2021 | 13.1× | (22.33%) |
| Jun 2021 | 16.9× | (92.85%) |
| Mar 2021 | 236× | — |
| 1 more quarters | Free account |
Against its own ten years
Low 0.0×
High 236×
Ten-year median
0.0×
Current reading's percentile
71
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRD Opus Genetics, Inc. compare | n/m |
| OBIO Orchestra BioMed Holdings, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| FENC Adherex Technologies Inc. compare | n/m |
| SRZN Surrozen, Inc. compare | n/m |
| AGMB AgomAb Therapeutics NV compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)